DE69716341D1 - Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen - Google Patents

Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen

Info

Publication number
DE69716341D1
DE69716341D1 DE69716341T DE69716341T DE69716341D1 DE 69716341 D1 DE69716341 D1 DE 69716341D1 DE 69716341 T DE69716341 T DE 69716341T DE 69716341 T DE69716341 T DE 69716341T DE 69716341 D1 DE69716341 D1 DE 69716341D1
Authority
DE
Germany
Prior art keywords
carnitines
inflammatory bowel
bowel diseases
alkanoyl
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716341T
Other languages
English (en)
Other versions
DE69716341T2 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE69716341D1 publication Critical patent/DE69716341D1/de
Application granted granted Critical
Publication of DE69716341T2 publication Critical patent/DE69716341T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69716341T 1996-06-06 1997-06-03 Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen Expired - Lifetime DE69716341T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000396A IT1284661B1 (it) 1996-06-06 1996-06-06 Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.

Publications (2)

Publication Number Publication Date
DE69716341D1 true DE69716341D1 (de) 2002-11-21
DE69716341T2 DE69716341T2 (de) 2003-06-05

Family

ID=11404269

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716341T Expired - Lifetime DE69716341T2 (de) 1996-06-06 1997-06-03 Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen

Country Status (14)

Country Link
US (2) US6013670A (de)
EP (1) EP0811376B1 (de)
JP (1) JP4171085B2 (de)
KR (1) KR100450293B1 (de)
AT (1) ATE226069T1 (de)
CA (1) CA2206995C (de)
DE (1) DE69716341T2 (de)
DK (1) DK0811376T3 (de)
ES (1) ES2185897T3 (de)
IT (1) IT1284661B1 (de)
MX (1) MX9704150A (de)
PT (1) PT811376E (de)
TW (1) TW585763B (de)
ZA (1) ZA974946B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
EP0972516A1 (de) * 1998-06-25 2000-01-19 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. L-Carnitin ersetzende Zusammensetzung ohne gastrointestinale Nebenwirkungen
WO2001066108A1 (en) * 2000-03-07 2001-09-13 Mucosal Therapeutics Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
JP4104834B2 (ja) * 2001-04-13 2008-06-18 株式会社東芝 Ｍｉｓ型電界効果トランジスタの製造方法
ITRM20040168A1 (it) * 2004-04-01 2004-07-01 Sigma Tau Ind Farmaceuti Composizione a rilascio modificato ph dipendente.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
CN100421648C (zh) * 2006-08-15 2008-10-01 苏州市立医院 氢化考的松灌肠剂及其制备方法
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi

Also Published As

Publication number Publication date
CA2206995A1 (en) 1997-12-06
MX9704150A (es) 1997-12-31
ITRM960396A0 (it) 1996-06-06
ITRM960396A1 (it) 1997-12-06
ES2185897T3 (es) 2003-05-01
US6143785A (en) 2000-11-07
DK0811376T3 (da) 2003-03-10
KR100450293B1 (ko) 2004-11-20
JPH1059845A (ja) 1998-03-03
TW585763B (en) 2004-05-01
ZA974946B (en) 1997-12-18
EP0811376A1 (de) 1997-12-10
CA2206995C (en) 2007-10-30
KR980000444A (ko) 1998-03-30
PT811376E (pt) 2003-03-31
JP4171085B2 (ja) 2008-10-22
IT1284661B1 (it) 1998-05-21
DE69716341T2 (de) 2003-06-05
US6013670A (en) 2000-01-11
EP0811376B1 (de) 2002-10-16
ATE226069T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
DE3784693D1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE122005000005I2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
FR2704418B1 (fr) Tube contenant un activateur de la coagulation du sang et son procede de preparation.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
DK0994743T3 (da) Behandling af inflammatoriske lidelser i tarm eller urinblære
DE69716341D1 (de) Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
MX9703975A (es) Nueva formulacion antitrombotica, proceso para su fabricacion y uso de la misma.
DE69215191D1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition